MCID: FLR001
MIFTS: 59

Filarial Elephantiasis

Categories: Infectious diseases, Rare diseases, Skin diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Filarial Elephantiasis

MalaCards integrated aliases for Filarial Elephantiasis:

Name: Filarial Elephantiasis 11 19 28 14 16
Lymphatic Filariasis 11 19 58 75 53 2 14 33
Elephantiasis 19 71
Filariasis 19 71
Infection by Wuchereria Bancrofti 71
Wuchereria Bancrofti Infection 19
Bancroftian Filarial Chyluria 11
Malayi Tropical Eosinphilia 19
Bancroftian Elephantiasis 11
Elephantiasis of Eyelid 11
Elephantiasis, Filarial 43
Bancroftian Filariasis 19
Filarial Elephantiases 71
Tropical Elephantiasis 33
Filarial Lymphangitis 33
Filarial Chylocele 33
Wuchereriasis 19
Elephantitis 19

Characteristics:


Prevelance:

Lymphatic Filariasis: >1/1000 (Specific population) 58

Age Of Onset:

Lymphatic Filariasis: All ages 58

Classifications:

Orphanet: 58  
Rare infectious diseases


Summaries for Filarial Elephantiasis

Orphanet: 58 Lymphatic filariasis (LF) is a severe form of filariasis (see this term), caused by the parasitic worms Wuchereria bancrofti, Brugia malayi and Brugia timori, and the most common cause of acquired lymphedema worldwide. LF is endemic to tropical and subtropical regions. The vast majority of infected patients are asymptomatic but it can also cause a variety of clinical manifestations, including limb lymphedema, genital anomalies (hydrocele, chylocele), elephantiasis in later stages of the disease (frequently in the lower extremities), and tropical pulmonary eosinophilia (nocturnal paroxysmal cough and wheezing, weight loss, low-grade fever, adenopathy, and pronounced blood eosinophilia). Renal involvement (hematuria, proteinuria, nephritic syndrome, glomerulonephritis), and mono-arthritis of the knee or ankle joint have also been reported.

MalaCards based summary: Filarial Elephantiasis, also known as lymphatic filariasis, is related to loiasis and onchocerciasis, and has symptoms including chyluria An important gene associated with Filarial Elephantiasis is IL10 (Interleukin 10), and among its related pathways/superpathways are Akt Signaling and Overview of interferons-mediated signaling pathway. The drugs Doxycycline and Glycerin have been mentioned in the context of this disorder. Affiliated tissues include skin, lung and testis, and related phenotypes are lymphadenopathy and predominantly lower limb lymphedema

CDC: 2 Lymphatic filariasis, considered globally as a neglected tropical disease (NTD), is a parasitic disease caused by microscopic, thread-like worms. The adult worms only live in the human lymph system. The lymph system maintains the body's fluid balance and fights infections. Lymphatic filariasis is spread from person to person by mosquitoes. People with the disease can suffer from lymphedema and elephantiasis and in men, swelling of the scrotum, called hydrocele. Lymphatic filariasis is a leading cause of permanent disability worldwide. Communities frequently shun and reject women and men disfigured by the disease. Affected people frequently are unable to work because of their disability, and this harms their families and their communities.

Disease Ontology: 11 A filariasis that is characterized by the thickening of the skin and underlying tissues, especially in the legs, male genitals and female breasts, caused by thread-like parasitic worms Wuchereria bancrofti, Brugia malayi or Brugia timori, which inhabit the lymphatics. These nematodes are transmitted by mosquitoes. Acute symptoms include fever, lymphadenitis, lymphangitis, funiculitis, and epididymitis. Chronic symptoms include abscesses, hyperkeratosis, polyarthritis, hydroceles, lymphedema, and elephantiasis.

GARD: 19 Lymphatic filariasis is a parasitic disease caused by microscopic, thread-like worms that only live in the human lymph system, which maintains the body's fluid balance and fights infections. It is spread from person to person by mosquitoes. Most infected people are asymptomatic and never develop clinical symptoms.

Wikipedia: 75 Lymphatic filariasis is a human disease caused by parasitic worms known as filarial worms. Most cases of... more...

Related Diseases for Filarial Elephantiasis

Diseases related to Filarial Elephantiasis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 720)
# Related Disease Score Top Affiliating Genes
1 loiasis 32.6 STH IL5 IL4 IL13 IL10
2 onchocerciasis 32.5 STH IL5 IL4 IL13
3 elephantiasis 31.2 STH IL5 IL4 IL13 IL10 GPT2
4 hypereosinophilic syndrome 31.0 IL9 IL5 IL4 IL13 IL10
5 pulmonary eosinophilia 31.0 IL5 IL4 IL13
6 ancylostomiasis 31.0 MT-CO1 IL5
7 schistosomiasis 30.8 IL9 IL5 IL4 IL13 IL10
8 dracunculiasis 30.8 STH MT-CO1
9 endomyocardial fibrosis 30.5 IL5 IL4 IL10
10 orchitis 30.5 IL10 FOXP3 CD4
11 ascaris lumbricoides infection 30.4 STH IL9 IL5 IL4 IL13 IL10
12 trichuriasis 30.3 STH IL9 IL13 IL10
13 scabies 30.3 STH IL5 IL4 IL13 CD4
14 trachoma 30.2 STH IL4 IL10
15 giardiasis 30.2 STH IL10 CD4
16 trypanosomiasis 30.2 TLR2 IL9 IL4 IL10 CD4
17 toxocariasis 30.2 STH IL5 IL4 IL13 IL10
18 cystic echinococcosis 30.2 MT-CO1 IL4 IL10 CD4
19 urinary schistosomiasis 30.2 STH IL5 IL4 IL13 IL10 CD4
20 urticaria 30.2 IL5 IL4 IL13 IL10 CD4
21 epidemic typhus 30.1 MT-CO1 IL10 CD4
22 strongyloidiasis 30.1 STH MT-CO1 IL5 IL4 IL13 IL10
23 leishmaniasis 30.1 TLR4 TLR2 IL5 IL4 IL13 IL10
24 myiasis 30.1 MT-CO1 LCOR
25 silicosis 30.1 TLR4 IL4 IL10
26 ige responsiveness, atopic 30.1 IL5 IL4 IL13 IL10
27 scrub typhus 30.1 TLR4 TLR2 IL10
28 alveolar echinococcosis 30.1 MT-CO1 IL5 IL4 IL10 CD4
29 tertiary syphilis 30.1 IL10 CD4
30 echinococcosis 30.1 TLR4 TLR2 MT-CO1 IL5 IL10
31 chlamydia 30.0 TLR4 TLR2 IL5 IL4 IL10
32 gnathomiasis 30.0 STH MT-CO1
33 osteomyelitis 30.0 TLR4 TLR2 IL4 IL10
34 acne 30.0 TLR4 TLR2 IL10
35 allergic disease 30.0 IL9 IL5 IL4 IL13 IL10 CD4
36 pulmonary tuberculosis 30.0 TLR4 TLR2 IL4 IL10
37 actinomycosis 30.0 IL10 CD4
38 anterior uveitis 30.0 TLR4 TLR2 IL10 CD4
39 angiostrongyliasis 30.0 MT-CO1 IL5 IL13
40 babesiosis 30.0 MT-CO1 IL10 CD4
41 filariasis 29.9 TLR4 TLR2 STH MT-CO1 IL5 IL4
42 exanthem 29.9 IL4 IL10 CD4
43 toxoplasmosis 29.9 IL5 IL4 IL10
44 leptospirosis 29.9 TLR2 IL4 IL10
45 keratoconjunctivitis 29.9 IL5 IL4 IL13
46 rheumatic heart disease 29.9 TLR2 IL4 IL10
47 tracheitis 29.9 IL10 CD4
48 malaria 29.9 TLR4 TLR2 MT-CO1 IL9 IL5 IL4
49 dysentery 29.9 TLR4 STH IL10 CD4
50 paragonimiasis 29.9 STH MT-CO1 IL5 IL13

Graphical network of the top 20 diseases related to Filarial Elephantiasis:



Diseases related to Filarial Elephantiasis

Symptoms & Phenotypes for Filarial Elephantiasis

Human phenotypes related to Filarial Elephantiasis:

58 30 (show all 34)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 lymphadenopathy 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0002716
2 predominantly lower limb lymphedema 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0003550
3 fatigue 58 30 Frequent (33%) Frequent (79-30%)
HP:0012378
4 hyperkeratosis 58 30 Frequent (33%) Frequent (79-30%)
HP:0000962
5 hyperpigmentation of the skin 58 30 Frequent (33%) Frequent (79-30%)
HP:0000953
6 pain 58 30 Frequent (33%) Frequent (79-30%)
HP:0012531
7 circulating immune complexes 58 30 Frequent (33%) Frequent (79-30%)
HP:0012224
8 hypereosinophilia 58 30 Frequent (33%) Frequent (79-30%)
HP:0032061
9 lymphadenitis 58 30 Frequent (33%) Frequent (79-30%)
HP:0002840
10 fever 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001945
11 cough 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0012735
12 abnormal lung morphology 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002088
13 abnormality of the scrotum 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0000045
14 orchitis 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0100796
15 vaginal hydrocele 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0100673
16 wheezing 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0030828
17 lymphangiectasis 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0031842
18 opportunistic bacterial infection 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0032260
19 restrictive ventilatory defect 30 Occasional (7.5%) HP:0002091
20 proteinuria 58 30 Very rare (1%) Very rare (<4-1%)
HP:0000093
21 nephrotic syndrome 58 30 Very rare (1%) Very rare (<4-1%)
HP:0000100
22 hematuria 58 30 Very rare (1%) Very rare (<4-1%)
HP:0000790
23 urethral obstruction 58 30 Very rare (1%) Very rare (<4-1%)
HP:0000796
24 glomerulonephritis 58 30 Very rare (1%) Very rare (<4-1%)
HP:0000099
25 ankle swelling 58 30 Very rare (1%) Very rare (<4-1%)
HP:0001785
26 no social interaction 58 30 Very rare (1%) Very rare (<4-1%)
HP:0008763
27 knee osteoarthritis 58 30 Very rare (1%) Very rare (<4-1%)
HP:0005086
28 epididymitis 58 30 Very rare (1%) Very rare (<4-1%)
HP:0000031
29 lymphedema 58 Very frequent (99-80%)
30 abnormality of the lymphatic system 58 Very frequent (99-80%)
31 abnormality of the kidney 58 Occasional (29-5%)
32 restrictive deficit on pulmonary function testing 58 Occasional (29-5%)
33 hydrocele testis 58 Occasional (29-5%)
34 opportunistic infection 58 Occasional (29-5%)

UMLS symptoms related to Filarial Elephantiasis:


chyluria

MGI Mouse Phenotypes related to Filarial Elephantiasis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.17 CD4 FOXP3 GPT2 HPGDS IFT43 IL10
2 immune system MP:0005387 9.93 CD4 FOXP3 HPGDS IL10 IL13 IL4
3 digestive/alimentary MP:0005381 9.91 CD4 FOXP3 IL10 IL13 IL4 IL5
4 mortality/aging MP:0010768 9.86 CD4 FOXP3 GATB GPT2 HPGDS IFT43
5 integument MP:0010771 9.28 CD4 FOXP3 HPGDS IL10 IL13 IL4

Drugs & Therapeutics for Filarial Elephantiasis

Drugs for Filarial Elephantiasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 30)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxycycline Approved, Investigational, Vet_approved Phase 3 564-25-0 54671203
2
Glycerin Approved, Investigational Phase 3 56-81-5 753
3
Petrolatum Approved, Investigational Phase 3 8009-03-8
4
Artenimol Approved, Experimental, Investigational Phase 3 71939-50-9 540327
5
Piperaquine Approved, Experimental, Investigational Phase 3 4085-31-8
6
Sodium citrate Approved, Investigational Phase 3 68-04-2 23431961
7
Diethylcarbamazine Approved, Investigational, Vet_approved Phase 3 90-89-1 3052
8
Moxidectin Approved, Investigational, Vet_approved Phase 3 113507-06-5 72728820
9
Citric acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
10 Eusol Phase 3
11
Sodium Hypochlorite Phase 3
12 Protective Agents Phase 3
13 Antimalarials Phase 3
14 Citrate Phase 3
15
Praziquantel Approved, Investigational, Vet_approved Phase 1 55268-74-1 4891
16
Benzimidazole Experimental, Investigational Phase 1 51-17-2 5798
17
Oxfendazole Investigational, Vet_approved Phase 1 53716-50-0 40854
18
Emodepside Investigational, Vet_approved Phase 1 155030-63-0
19 Pharmaceutical Solutions Phase 1
20 Toltrazuril Phase 1
21
Mebendazole Approved, Vet_approved 31431-39-7 4030
22
Piperazine Approved, Vet_approved 110-85-0 4837
23
Permethrin Approved, Investigational 52645-53-1 40326
24 Calcium, Dietary
25 Anticoagulants
26 Piperazine citrate
27 DMP 777 157341-41-8
28 Chelating Agents
29 Liver Extracts
30
Calcium Nutraceutical 7440-70-2 271

Interventional clinical trials:

(show all 50)
# Name Status NCT ID Phase Drugs
1 Impact of Albendazole -Ivermectin Combination Treatment on Wuchereria Bancrofti Infection and Transmission in Mali Completed NCT02784743 Phase 4 ''albendazole'' and ''ivermectin''
2 Cluster Randomized Community-based Trial of Annual Versus Biannual Single-dose Ivermectin Plus Albendazole Against Wuchereria Bancrofti Infection in Human and Mosquito Populations Completed NCT03036059 Phase 4 400 μg/kg Ivermectin + 400 mg Albendazole
3 Safety of the Co-administration of Azithromycin, Albendazole and Ivermectin Versus Standard Treatment Regimens During Mass Drug Administration (MDA) in Ethiopia: a Cluster-randomized Trial Completed NCT03570814 Phase 4 Administration of Albendazole on Day 1;Administration of Ivermectin on Day 1;Administration of Azithromycin on Day 1;Administration of Azithromycin on Day 15
4 AZIVAL 2: A Double-blind Cluster-randomized Placebo-controlled Study on the Safety of Integrated Treatment of Trachoma and Lymphatic Filariasis in Children and Adults With Azithromycin, Ivermectin and Albendazole Withdrawn NCT01903057 Phase 4 azithromycin;ivermectin;albendazole;placebo
5 Repeat Ivermectin Mass Drug Administrations for Control of Malaria: a Pilot Safety and Efficacy Study Completed NCT02509481 Phase 2, Phase 3 Ivermectin;Albendazole
6 A Multi-center, Double-blind, Randomized, 24-month Study, to Compare the Efficacy of Doxycycline Once Daily for 6 Weeks Versus Placebo in Improving Filarial Lymphedema Independent of Active Filarial Infection Completed NCT02927496 Phase 3 Doxycycline;Placebo
7 A Multi-center, Double-blind, Randomized, 24-month Study, to Compare the Efficacy of Doxycycline Once Daily for 6 Weeks Versus Placebo in Improving Filarial Lymphedema Independent of Active Filarial Infection Completed NCT02929134 Phase 3 Doxycycline;Placebo
8 A Multi-center, Double-blind, Randomized, 24-month Study, to Compare the Efficacy of Doxycycline Once Daily for 6 Weeks Versus Placebo in Improving Filarial Lymphedema Independent of Active Filarial Infection Completed NCT02929121 Phase 3 Doxycycline;Placebo
9 A Randomised Controlled Trial to Evaluate the Effect of a New Skin Care Regimen on Skin Barrier Function in Those With Podoconiosis in Ethiopia Completed NCT02839772 Phase 3
10 A Cluster Randomised Trial of the Safety of Co-Administration of IDA (Ivermectin, Diethylcarbamazine and Albendazole) & Azithromycin for Integrated Treatment of Neglected Tropical Diseases Completed NCT03676140 Phase 3 Albendazole on Day 1;Ivermectin on Day 1;Diethylcarbamazine on day 1;Azithromycin on Day 1;Azithromycin on Day 8
11 Adjunctive Ivermectin Mass Drug Administration for Malaria Control on the Bijagos Archipelago of Guinea Bissau: A Cluster-randomized Placebo-controlled Trial Recruiting NCT04844905 Phase 3 Ivermectin;Placebo;Dihydroartemisinin-piperaquine
12 Field Studies on the Feasibility of Interrupting the Transmission of Soil-transmitted Helminths (STH) DeWorm3 Project Recruiting NCT03014167 Phase 3 Albendazole
13 A Clinical Trial to Assess the Safety and Efficacy of Moxidectin Combination Treatments vs. Ivermectin Combination Treatments for Bancroftian Filariasis Active, not recruiting NCT04410406 Phase 3 Ivermectin;Diethylcarbamazine;Albendazole;Moxidectin
14 Treatment of Mansonella Perstans Infection in an Area Coendemic for Lymphatic Filariasis: A Pilot Study of the Effects of Doxycycline Completed NCT00340691 Phase 2 Doxycycline
15 Evaluate Triple-Drug Therapy With Diethylcarbamize (DEC), Albendazole (ALB) and Ivermectin (IVM) That Could Accelerate LF Elimination Outside of Africa Completed NCT01975441 Phase 2 Diethylcarbamazine;Albendazole;Ivermectin
16 Effect of Albendazole Dose and Interval on Brugia Malayi Microfilarial Clearance in India: A Randomized, Open Label Study Completed NCT00511004 Phase 2 Albendazole;Diethylcarbamazine
17 Effect of Albendazole Dose and Interval on Wuchereria Bancrofti Microfilarial Clearance in India: A Randomized, Open Label Study Completed NCT00375583 Phase 2 DEC/Albendazole
18 A Pharmacokinetic and Pharmacodynamic Evaluation of Co-Administration of IDA (Ivermectin, Diethylcarbamazine and Albendazole) & Azithromycin for Integrated Treatment of Neglected Tropical Diseases Completed NCT03664063 Phase 2 Azithromycin;Albendazole;Ivermectin;Diethylcarbamazine
19 Effect of Albendazole and Ivermectin Dose on Wuchereria Bancrofti Microfilarial Clearance in Mali: A Randomized, Open Label Study Completed NCT00339417 Phase 2 Albendazole;Ivermectin
20 Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Single Dose Treatment With Diethylcarbamazine, Albendazole and Ivermectin in Humans With and Without Wuchereria Bancrofti Infection in Côte d'Ivoire Completed NCT02845713 Phase 1 Ivermectin, Diethylcarbamazine Albendazole (IDA)
21 A Phase 1, Bioavailability Study to Investigate the Pharmacokinetics, Safety and Tolerability of an Oxfendazole Tablet Formulation in a Randomized, Double-Blind, Placebo-Controlled Design After Single and Multiple Oral Dosing in Healthy Adult Volunteers Completed NCT04920292 Phase 1 Oxfendazole;Placebo
22 A Phase 1, Single-Blind, Randomized, Placebo Controlled, Parallel-Group, Multiple-Dose-Escalation Study to Investigate Safety, Tolerability, and Pharmacokinetics of Emodepside (BAY 44-4400) After Oral Dosing in Healthy Male Subjects Completed NCT03383614 Phase 1 LSF emodepside (BAY 44-4400) or matching placebo
23 Phase1,Randomized,Open-Label,Parallel-Group,Relative Bioavailability Study to Investigate PK,Including Food Effect,Safety and Tolerability of Single Doses of New Immediate Release Tablet Formulations of Emodepside (BAY 44-4400),Compared to Oral Solution,in Healthy Male Subjects Completed NCT03383523 Phase 1 Emodepside (BAY 44-4400)
24 Development of AWZ1066S, a Small Molecule Anti-Wolbachia Candidate Macrofilaricide Drug Not yet recruiting NCT05084560 Phase 1 AWZ1066S;Placebo
25 Spontaneous Antigenemia in Loiasis, A Study of the Loiasis Antigens Responsible for Cross-reactivity in the Rapid Diagnostic Test for Lymphatic Filariasis Unknown status NCT04258670
26 Prevalence Survey for Innovative and Intensified Disease Management (IDM) Neglected Tropical Diseases (NTDs): A Cluster Randomised Two-stage Active Case Search for IDM-NTDs in Liberia Unknown status NCT03683745
27 Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis for Liberia Completed NCT01905436 Annual versus Semiannual Albendazole plus Ivermectin Mass Drug Administration
28 Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis Completed NCT01905423 Albendazole (annual);Diethylcarbamazine (annual);Albendazole (semiannual);Diethylcarbamazine (semiannual)
29 Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis for Ivory Coast Completed NCT02032043 Annual versus Semiannual Albendazole plus Ivermectin MDA
30 Research for Elimination of Lymphatic Filariasis (ICIDR) Completed NCT00406627
31 Community Studies to Monitor the Impact of Triple Drug Therapy Relative to Double Drug Therapy on Lymphatic Filariasis Infection Indicators Completed NCT03352206 2 drug dose - DA;3 drug dose - IDA
32 Alternative Chemotherapies for Lymphatic Filariasis (LF) Treatment and Elimination in Africa [Cote d'Ivoire] Completed NCT02974049 Albendazole;Ivermectin;Diethylcarbamazine
33 Evaluation of Antibacterial Soap for Treatment of Lymphedema and Elephantiasis in an Area Endemic for Lymphatic Filariasis Completed NCT00139100 antimicrobial agent in soap
34 Community Based Safety Study of 2-drug (Diethylcarbamazine and Albendazole) Versus 3-drug (Ivermectin, Diethylcarbamazine and Albendazole) Therapy for Lymphatic Filariasis, Scabies and Soil Transmitted Helminths in Fiji Completed NCT03177993 3 drug dose - IDA;3 drug dose - IDA with second dose of ivermectin;2 drug dose - DA
35 Disability and Quality of Life in Patients With Lymphatic Filariasis in Rural Southern India Completed NCT01629771
36 Studies on the Interaction Between HIV Infection, Lymphatic Filariasis and Diethylcarbamazine Completed NCT00295698 Diethylcarbamazine
37 Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis: Monitoring Efficacy of Ongoing Treatment Programs in Papua New Guinea Completed NCT03268252
38 A Pharmacovigilance Study on the Safety of Integrated Treatment of Trachoma and Lymphatic Filariasis in Children and Adults Living in the Sikasso Region of Mali Completed NCT01586169 triple co administration at once of the combination of Albendazole + ivermectin + azithromycin
39 Community Based Safety Study of 2-drug (Diethylcarbamazine and Albendazole) Versus 3-drug (Ivermectin, Diethylcarbamazine and Albendazole) Therapy for Lymphatic Filariasis Completed NCT02899936 3 drug dose - IDA;2 drug dose - DA
40 Promoting Consistent Shoe Use Among Children At High Risk for Podoconiosis Completed NCT01160523
41 Determination of the Prevalence of LF Infection in Districts Not Included in LF Control Activities and of the Basis for Integrated Implementation of LF - Onchocerciasis Elimination Strategies in Potentially Co-endemic Areas Completed NCT03131401
42 Coinfection With Plasmodium Falciparum and Wuchereria Bancrofti: Clinical, Epidemiologic and Immunologic Implications Completed NCT00471666
43 Research for Elimination of Human Filariasis Completed NCT00145223
44 Exhaled NO Testing in Filariasis Completed NCT01628497
45 Effect of Filarial Infection on Antigen-Specific Immune Responses in Latent Tuberculosis Completed NCT01547884
46 Changes in HIV Viral Load in Patients Undergoing Treatment for Filarial Infection Completed NCT00344279
47 When is it Appropriate to Stop? Applied Field Research to Develop an M&E Strategy to Recruiting NCT04124250
48 Host Response to Infection and Treatment in the Filarial Diseases of Humans Recruiting NCT00001230
49 Efficacy of Higher Albendazole and Ivermectin Doses on Wuchereria Bancrofti Microfilarial Clearance in Malawi, Open Label Study Terminated NCT01213576 Albendazole 400mg and ivermectin 200mcg/kg;Albendazole and ivermectin;albendazole 800mg and ivermectin 400mcg/kg bi-annually
50 Investigation of the Pathogenesis of Podoconiosis Using RNA-seq and Immunopathologic Approaches Terminated NCT01939431

Search NIH Clinical Center for Filarial Elephantiasis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Ivermectin

Cochrane evidence based reviews: elephantiasis, filarial

Genetic Tests for Filarial Elephantiasis

Genetic tests related to Filarial Elephantiasis:

# Genetic test Affiliating Genes
1 Filarial Elephantiasis 28

Anatomical Context for Filarial Elephantiasis

Organs/tissues related to Filarial Elephantiasis:

MalaCards : Skin, Lung, Testis, Kidney, Lymph Node, Breast, Liver

Publications for Filarial Elephantiasis

Articles related to Filarial Elephantiasis:

(show top 50) (show all 8195)
# Title Authors PMID Year
1
Regulation of parasite antigen-driven immune responses by interleukin-10 (IL-10) and IL-12 in lymphatic filariasis. 53 62
9125556 1997
2
Immunoregulation in human lymphatic filariasis: the role of interleukin 10. 53 62
7501419 1995
3
Disseminated histoplasmosis in a patient with chronic lymphoedema. 62
36193195 2022
4
Immunomodulatory effects of chitosan nanoparticles as vaccine delivery agent against lymphatic filariasis through mucosal immunization. 62
36220408 2022
5
Effects of blood meal sources on the biological characteristics of Aedes aegypti and Culex pipiens (Diptera: Culicidae). 62
36187452 2022
6
First Report of Sarconema eurycerca Heart Infection in Mute Swans in Serbia. 62
36107330 2022
7
Visualization of the Linear and Spatial Organization of Chromosomes in Mosquitoes. 62
35960626 2022
8
An overview of human helminthioses in Vietnam: Their prevention, control and lessons learnt. 62
36375522 2022
9
The microbial community associated with Parascaris spp. infecting juvenile horses. 62
36333754 2022
10
A large case series of travel-related Mansonella perstans (vector-borne filarial nematode): a TropNet study in Europe. 62
35417002 2022
11
Integrated xenosurveillance of Loa loa, Wuchereria bancrofti, Mansonella perstans and Plasmodium falciparum using mosquito carcasses and faeces: A pilot study in Cameroon. 62
36322515 2022
12
RNAi-mediated knockdown of arginine kinase genes leads to high mortality and negatively affect reproduction and blood-feeding behavior of Culex pipiens pallens. 62
36413567 2022
13
Novel Genome Sequences and Evolutionary Dynamics of the North American Anopheline Species Anopheles freeborni, crucians, quadrimaculatus, and albimanus. 62
36377778 2022
14
Antifilarial efficacy of andrographolide: Ex vivo studies on bovine filarial parasite Setaria cervi. 62
35985449 2022
15
Unilateral Lower Extremity Elephantiasis. 62
36449404 2022
16
Saxophone penis - An intriguing manifestation of gastrointestinal metastasis. 62
36352346 2022
17
Correction: Multi-drug resistant bacteria isolates from lymphatic filariasis patients in the Ahanta West District, Ghana. 62
36324092 2022
18
Prevalence and risk factors for blood filariasis among HIV-infected adults in Gabon, Central Africa: a pilot study. 62
35474144 2022
19
Correction to: No evidence of lymphatic filariasis transmission in Bamako urban setting after three mass drug administration rounds. 62
36355182 2022
20
Correction: India can consider integration of three eliminable disease control programmes on malaria, lymphatic filariasis, and visceral leishmaniasis. 62
36409694 2022
21
No evidence of lymphatic filariasis transmission in Bamako urban setting after three mass drug administration rounds. 62
36066741 2022
22
Comparative evaluation of different versions of exposure-free mosquito electrocuting traps and barrier screen trap for monitoring outdoor densities and biting time phenotypes by malaria and filariasis vectors in Tanzania. 62
36369172 2022
23
Assessment of factors related to individuals who were never treated during mass drug administration for lymphatic filariasis in Ambon City, Indonesia. 62
36367853 2022
24
Filariasis in an alcoholic male-coincidental or causal association? 62
36318173 2022
25
Hemorrhagic shock due to ruptured lower limb vascular malformation in a neurofibromatosis type 1 patient: A case report. 62
36387817 2022
26
Knowledge, attitude, and practice regarding mosquito-borne diseases among migrant laborers from a migrant settlement in Ponekkara, Ernakulam Kerala. 62
36412475 2022
27
Evaluating and mitigating the potential indirect effect of COVID-19 on control programmes for seven neglected tropical diseases: a modelling study. 62
36240827 2022
28
Multi-drug resistant bacteria isolates from lymphatic filariasis patients in the Ahanta West District, Ghana. 62
36221074 2022
29
Spatially Explicit Environmental Factors Associated with Lymphatic Filariasis Infection in American Samoa. 62
36288036 2022
30
A rare case of ocular filariasis caused by Brugia malayi. 62
35659633 2022
31
Prevalence, probability, and characteristics of malaria and filariasis co-infections: A systematic review and meta-analysis. 62
36269701 2022
32
Factors Associated with the Acceptability of Mass Drug Administration for Filariasis: A Systematic Review. 62
36232271 2022
33
Filarial thioredoxin reductase: A possible means to exterminate lymphatic filariasis. 62
36050138 2022
34
Mass drug administration for lymphatic filariasis elimination amidst COVID-19 pandemic in Odisha, India: A step towards achieving SDG-3. 62
35770893 2022
35
Communication in Neglected Tropical Diseases' elimination: A scoping review and call for action. 62
36228006 2022
36
Diethylcarbamazine mediated potentiation of emodepside induced paralysis requires TRP-2 in adult Brugia malayi. 62
36368250 2022
37
Mosquito Vectors (Diptera: Culicidae) and Mosquito-Borne Diseases in North Africa. 62
36292910 2022
38
Characterization of the genetics and epidemiology of Brugia sp. in domestic dogs in Chad, Africa. 62
36184112 2022
39
Bio-efficacy of Soil Actinomycetes and an Isolated Molecule 1,2-Benzenedicarboxylic Acid from Nonomuraea sp. Against Culex quinquefasciatus Say and Aedes aegypti L. Mosquitoes (Diptera: Culicidae). 62
34806140 2022
40
Nanopore Sequencing Using the Full-Length 16S rRNA Gene for Detection of Blood-Borne Bacteria in Dogs Reveals a Novel Species of Hemotropic Mycoplasma. 62
36250862 2022
41
Modulation of immunological responses by aqueous extract of Datura stramonium L. seeds on cyclophosphamide-induced immunosuppression in Wistar rats. 62
36261807 2022
42
Computational identification and experimental validation of anti-filarial lead molecules targeting metal binding/substrate channel residues of Cu/Zn SOD1 from Wuchereria bancrofti. 62
36305196 2022
43
Microfilaria in cervicovaginal Pap smears: A common parasite hiding in an unusual site: Short series of four cases with literature review. 62
36269616 2022
44
Sustainable development through the bio-fabrication of ecofriendly ZnO nanoparticles and its approaches to toxicology and environmental protection. 62
36320445 2022
45
A call for loiasis to be added to the WHO list of neglected tropical diseases. 62
35500592 2022
46
Alteration of rhesus macaque serum N-glycome during infection with the human parasitic filarial nematode Brugia malayi. 62
36131114 2022
47
The Domestic Dog as a Laboratory Host for Brugia malayi. 62
36297129 2022
48
Essential Oils from Cameroonian Aromatic Plants as Effective Insecticides against Mosquitoes, Houseflies, and Moths. 62
36145754 2022
49
A dog presenting with syncope due to two different etiologies. 62
36382040 2022
50
Misleading eosinophil counts in migration-associated malaria: do not miss hidden helminthic co-infections. 62
35934309 2022

Variations for Filarial Elephantiasis

Expression for Filarial Elephantiasis

Search GEO for disease gene expression data for Filarial Elephantiasis.

Pathways for Filarial Elephantiasis

Pathways related to Filarial Elephantiasis according to GeneCards Suite gene sharing:

(show all 28)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.29 TLR4 TLR2 IL9 IL5 IL4 IL13
2
Show member pathways
12.53 IL9 IL5 IL4 IL13 IL10
3
Show member pathways
12.03 IL5 IL4 IL10 CD4
4
Show member pathways
11.91 TLR4 TLR2 IL5 IL13
5 11.88 CD4 IL10 IL4 IL5
6 11.85 IL4 IL13 IL10
7
Show member pathways
11.8 TLR4 TLR2 IL10 CD4
8 11.8 IL5 IL4 IL13 IL10 FOXP3
9
Show member pathways
11.74 TLR4 TLR2 IL4 CD4
10 11.7 CD4 IL10 IL13 IL4 IL5 IL9
11 11.68 IL5 IL4 IL13
12 11.66 TLR4 IL10 CD4
13 11.63 TLR4 IL4 IL10
14 11.61 IL10 IL4 IL5
15 11.6 CD4 FOXP3 IL4
16
Show member pathways
11.58 IL5 IL4 FOXP3
17 11.54 IL5 IL4 IL13
18 11.51 IL5 IL4 IL10
19
Show member pathways
11.27 TLR4 TLR2 IL5 IL4 IL13 IL10
20 11.26 IL9 IL5 IL4 IL13
21 11.14 IL5 IL4 IL13 IL10
22 11.12 IL5 IL4 IL13 IL10 CD4
23 10.97 IL9 IL5 IL4 IL13 IL10
24 10.92 IL9 IL5 IL4 IL13 IL10
25 10.83 IL9 IL5 IL4 IL13 IL10 FOXP3
26 10.81 IL4 CD4
27 10.75 IL9 IL5 IL4 IL13
28 10.56 TLR4 TLR2

GO Terms for Filarial Elephantiasis

Biological processes related to Filarial Elephantiasis according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 10.33 TLR4 TLR2 IL9 IL5 IL13 FOXP3
2 negative regulation of inflammatory response GO:0050728 10.13 IL4 IL13 IL10 FOXP3
3 T cell activation GO:0042110 10.09 IL4 FOXP3 CD4
4 negative regulation of type II interferon production GO:0032689 10.07 TLR4 IL10 FOXP3
5 negative regulation of endothelial cell apoptotic process GO:2000352 10.03 IL4 IL13 IL10
6 B cell proliferation GO:0042100 10 TLR4 IL9 IL10
7 positive regulation of immunoglobulin production GO:0002639 10 IL5 IL13 IL10
8 microglial cell activation GO:0001774 9.99 TLR2 IL4 IL13
9 negative regulation of tumor necrosis factor production GO:0032720 9.97 TLR4 IL4 IL10 FOXP3
10 response to lipopolysaccharide GO:0032496 9.92 FOXP3 IL10 IL13 TLR2 TLR4
11 type 2 immune response GO:0042092 9.91 IL4 IL10
12 positive regulation of macrophage activation GO:0043032 9.91 TLR4 IL13 IL10
13 negative regulation of chronic inflammatory response GO:0002677 9.88 FOXP3 IL4
14 macrophage activation GO:0042116 9.88 TLR4 IL4 IL13
15 regulation of isotype switching GO:0045191 9.87 IL10 IL4
16 negative regulation of complement-dependent cytotoxicity GO:1903660 9.84 IL4 IL13
17 positive regulation of matrix metallopeptidase secretion GO:1904466 9.8 TLR2 TLR4
18 positive regulation of cellular response to macrophage colony-stimulating factor stimulus GO:1903974 9.78 TLR4 TLR2
19 asparaginyl-tRNA aminoacylation GO:0006421 9.76 NARS2 NARS1
20 positive regulation of B cell proliferation GO:0030890 9.76 TLR4 IL5 IL4 IL13
21 positive regulation of MHC class II biosynthetic process GO:0045348 9.73 TLR4 IL4 IL10
22 lymphocyte proliferation GO:0046651 9.61 TLR4 FOXP3
23 positive regulation of interleukin-10 production GO:0032733 9.56 TLR4 TLR2 IL4 IL13
24 immune response GO:0006955 9.47 TLR4 TLR2 IL9 IL5 IL4 IL13

Molecular functions related to Filarial Elephantiasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.85 IL9 IL5 IL4 IL13 IL10
2 lipopolysaccharide immune receptor activity GO:0001875 9.56 TLR4 TLR2
3 cytokine receptor binding GO:0005126 9.13 IL9 IL4 IL13
4 asparagine-tRNA ligase activity GO:0004816 8.92 NARS2 NARS1

Sources for Filarial Elephantiasis

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....